000 04821nam a22003735i 4500
001 277931
003 MX-SnUAN
005 20160429153841.0
007 cr nn 008mamaa
008 150903s2006 xxu| o |||| 0|eng d
020 _a9780387337067
_99780387337067
024 7 _a10.1007/0387337067
_2doi
035 _avtls000331088
039 9 _a201509030712
_bVLOAD
_c201404120605
_dVLOAD
_c201404090345
_dVLOAD
_c201401311402
_dstaff
_y201401301201
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRM1-950
100 1 _aTing, Naitee.
_eeditor.
_9301140
245 1 0 _aDose Finding in Drug Development /
_cedited by Naitee Ting.
264 1 _aNew York, NY :
_bSpringer New York,
_c2006.
300 _axiv, 248 páginas, 48 ilustraciones
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aStatistics for Biology and Health,
_x1431-8776
500 _aSpringer eBooks
505 0 _aand New Drug Development Process -- Dose Finding Based on Preclinical Studies -- Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose -- Dose-Finding in Oncology—Nonparametric Methods -- Dose Finding in Oncology—Parametric Methods -- Dose Response: Pharmacokinetic–Pharmacodynamic Approach -- General Considerations in Dose–Response Study Designs -- Clinical Trial Simulation—A Case Study Incorporating Efficacy and Tolerability Dose Response -- Analysis of Dose–Response Studies—Emax Model -- Analysis of Dose–Response Studies—Modeling Approaches -- Multiple Comparison Procedures in Dose Response Studies -- Partitioning Tests in Dose–Response Studies with Binary Outcomes -- Analysis of Dose–Response Relationship Based on Categorical Outcomes -- Power and Sample Size for Dose Response Studies.
520 _aWhen you go to the pharmacy and fill a prescription, have you ever wondered if the dose of the medication is right for you? Can the dose be too low so that the drug will not work? Can the dose be too high that it may cause some potential problem? How do people learn about dosing information? This book answers some of these questions. Dosing information on the drug label is based on discussion and agreement between the pharmaceutical manufacturer and the drug regulatory agency. A drug label is a high level summary of results obtained from many scientific experiments. Scientists with biological, chemical, medical, or statistical background working in the pharmaceutical industry designed and executed these experiments to obtain information to help understand the dosing information. This book introduces the drug development process, the design and analysis of clinical trials. Many of the discussions are based on applications of statistical methods in the design and analysis of dose response studies. Although the book is prepared mainly for statisticians/biostatisticians, it also serves as a useful reference to a variety of professionals working for the pharmaceutical industry. The potential readers include pharmacokienticists, clinical scientists, clinical pharmacologists, pharmacists, project managers, pharmaceutical scientists, clinicians, programmers, data managers, regulatory specialists, and study report writers. This book is also a good reference for professionals working in a drug regulatory environment, for example, the FDA. Scientists and/or reviewers from both U.S. and foreign drug regulatory agencies can benefit greatly from this book. In addition, statistical and medical professionals in academia may find this book helpful in understanding the drug development process and practical concerns in selecting doses for a new drug. Naitee Ting received his Ph. D. in statistics from Colorado State University in 1987 and joined Pfizer Research right after obtaining his Ph. D. Dr. Ting is currently an Associate Director of Biostatistics in Pfizer Global Research and Development, supporting clinical development of new drugs. He has over 18 years of experiences in designing and analyzing late phase clinical trials. During his tenure at Pfizer, Dr. Ting has published more than 20 statistical papers in peer-reviewed journals and book chapters. He has also taught clinical trials courses at the University of Connecticut and University of Rhode Island.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9780387290744
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/0-387-33706-7
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c277931
_d277931